Cargando…

Long-term efficacy and toxicity of abacavir/lamivudine/nevirapine compared to the most prescribed ARV regimens before 2013 in a French Nationwide Cohort Study

Data on the long-term efficacy and safety of abacavir/lamivudine (ABC/3TC) and nevirapine (NVP) are scarce. This combination has the advantage of simplifying treatment and improving long-term tolerance. The aim of this study was to compare the rate of any discontinuation of antiretroviral (ARV) regi...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Boissieu, Paul, Dramé, Moustapha, Raffi, François, Cabie, André, Poizot-Martin, Isabelle, Cotte, Laurent, Garraffo, Rodolphe, Delobel, Pierre, Huleux, Thomas, Rey, David, Bani-Sadr, Firouzé
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2016
Materias:	4850
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5402604/ https://www.ncbi.nlm.nih.gov/pubmed/27631261 http://dx.doi.org/10.1097/MD.0000000000004890

Ejemplares similares

Comparative Effectiveness of First Antiretroviral Regimens in Clinical Practice Using a Causal Approach
por: Cuzin, Lise, et al.
Publicado: (2015)

Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression: A prospective cohort study
por: Llibre, Josep M., et al.
Publicado: (2016)

Case report of Triumeq (abacavir/dolutegravir/lamivudine) associated rhabdomyolysis in a human immunodeficiency virus (HIV) infected patient
por: Saad, Muhammad, et al.
Publicado: (2019)

Effectiveness and tolerability of abacavir-lamivudine-nevirapine (ABC/3TC/NVP) in a multicentre cohort of HIV-infected, ARV-naïve patients
por: Podzamczer, Daniel, et al.
Publicado: (2014)

Antiretroviral therapy as a risk factor for chronic kidney disease: Results from traditional regression modeling and causal approach in a large observational study
por: Cuzin, Lise, et al.
Publicado: (2017)

Real-world efficacy and safety of dolutegravir plus lamivudine versus tenofovir plus lamivudine and efavirenz in ART-naïve HIV-1-infected adults
por: Li, Jin, et al.
Publicado: (2022)

First-line cART regimen impacts the course of CD8(+) T-cell counts in HIV-infected patients that achieve sustained undetectable viral load.
por: Poizot-Martin, Isabelle, et al.
Publicado: (2016)

HIV-related excess mortality and age-related comorbidities in patients with HIV aged ≥60: a relative survival analysis in the French Dat’AIDS cohort
por: Hentzien, Maxime, et al.
Publicado: (2019)

Higher rates of HBsAg clearance with tenofovir-containing therapy in HBV/HIV co-infection
por: Gantner, Pierre, et al.
Publicado: (2019)

Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir
por: Gianotti, Nicola, et al.
Publicado: (2016)

The role of CYP2B6 516G>T polymorphism on efavirenz/nevirapine toxicity. Implications on treatment outcomes: Lessons from Botswana
por: Maseng, Monkgomotsi J., et al.
Publicado: (2022)

Nevirapine plasma concentration is associated with virologic failure and the emergence of drug-resistant mutations among HIV patients in Kenya: A cross sectional study
por: Omondi, Evans Okumu, et al.
Publicado: (2022)

Virological outcomes in ARV-naïve patients switching or not from a first successful boosted PI-regimen to efavirenz, nevirapine or abacavir regimens
por: Bommenel, T, et al.
Publicado: (2010)

Antiretroviral exposure and comorbidities in an aging HIV-infected population: The challenge of geriatric patients
por: Allavena, Clotilde, et al.
Publicado: (2018)

Tolerance and durability of abacavir/lamivudine (ABC/3TC)-containing regimens: results from a large prospective French cohort
por: Cuzin, L, et al.
Publicado: (2010)

Efficacy and safety of 400 mg efavirenz versus standard 600 mg dose when taken with tenofovir and lamivudine combination in Indian adult patients with HIV-1 infection: An open-label, interventional, randomized, non-inferiority trial
por: Dravid, Ameet, et al.
Publicado: (2022)

Switch to Ritonavir-Boosted versus Unboosted Atazanavir plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical Practice
por: Gantner, Pierre, et al.
Publicado: (2016)

Derivation and internal validation of a mortality risk index for aged people living with HIV: The Dat'AIDS score
por: Hentzien, Maxime, et al.
Publicado: (2018)

Environmental Risk Characterization of an Antiretroviral (ARV) Lamivudine in Ecosystems
por: Omotola, Elizabeth Oyinkansola, et al.
Publicado: (2021)

Abacavir/lamivudine combination in the treatment of HIV: a review
por: Sivasubramanian, Geetha, et al.
Publicado: (2010)

Kaposi sarcoma among people living with HIV in the French DAT’AIDS cohort between 2010 and 2015
por: Poizot‐Martin, I., et al.
Publicado: (2020)

Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination
por: Virlogeux, Victor, et al.
Publicado: (2017)

Interactions of Tenofovir, Lamivudine, Abacavir and Didanosine in Primary Human Cells
por: Janneh, Omar, et al.
Publicado: (2011)

Twenty-four-week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/lamivudine as first-line antiretroviral therapy: a randomized double-blind trial (NORA)
Publicado: (2008)

Too fast to stay on track? Shorter time to first anti-retroviral regimen is not associated with better retention in care in the French Dat’AIDS cohort
por: Cuzin, L., et al.
Publicado: (2019)

Efficacy and tolerability of Etravirine in HIV-1 adult patients: Results of a large French prospective cohort
por: Allavena, Clotilde, et al.
Publicado: (2014)

MELD Score Kinetics in Decompensated HIV+/HCV+ Patients: A Useful Prognostic Tool (ANRS HC EP 25 PRETHEVIC Cohort Study)
por: Gelu-Simeon, Moana, et al.
Publicado: (2015)

An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy
por: M. Llibre, Josep, et al.
Publicado: (2016)

Safety analysis of Epzicom® (lamivudine/abacavir sulfate) in post-marketing surveillance in Japan†
por: Kurita, Tomoko, et al.
Publicado: (2014)

Correction: An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy
por: Llibre, Josep M., et al.
Publicado: (2016)

Incidence of cervical, breast and colorectal cancers between 2010 and 2015 in people living with HIV in France
por: Rojas Rojas, Teresa, et al.
Publicado: (2022)

The F4/AS01(B) HIV-1 Vaccine Candidate Is Safe and Immunogenic, But Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults: A Randomized Controlled Trial
por: Dinges, Warren, et al.
Publicado: (2016)

An indirect comparison of efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir and dolutegravir + abacavir/lamivudine
por: Rogatto, Felipe, et al.
Publicado: (2014)

Combination dolutegravir–abacavir–lamivudine in the management of HIV/AIDS: clinical utility and patient considerations
por: Cruciani, Mario, et al.
Publicado: (2015)

Efficacy and safety of the switch of Triumeq® to generic (abacavir + lamivudine) + Tivicay®: data at 24 weeks
por: Olalla, Julián, et al.
Publicado: (2018)

Abacavir/dolutegravir/lamivudine: Delayed hepatotoxicity and drug-induced liver injury: case report
Publicado: (2021)

A Korean Post-Marketing Study of Abacavir/Dolutegravir/Lamivudine in Patients with HIV-1
por: Shin, Sang-Kyu, et al.
Publicado: (2023)

Intrinsic Replication Competences of HIV Strains After Zidovudine/Lamivudine/Nevirapine Treatment in the Philippines
por: Kageyama, Seiji, et al.
Publicado: (2019)

Correction to: efficacy and safety of the switch of Triumeq® to generic (abacavir + lamivudine) + Tivicay®: data at 24 weeks
por: Olalla, Julián, et al.
Publicado: (2023)

Risk Factors for Acute and Early HIV Infection Among Men Who Have Sex With Men (MSM) in San Diego, 2008 to 2014: A Cohort Study
por: Hoenigl, Martin, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_n42a1lq3fl6a0rbr62upc3dgve